BC Week In Review | Apr 13, 2018
Company News

Oncology Venture licenses dovitinib from Novartis

Oncology Venture Sweden AB (AktieTorget:OV) exercised its option and will receive exclusive, worldwide rights to develop and commercialize dovitinib (TKI258) from Novartis AG (NYSE:NVS; SIX:NOVN). Novartis will receive an upfront payment and is eligible for...
BC Innovations | Jul 14, 2016
Distillery Therapeutics

Therapeutics: Multiple kinase targets; an undisclosed target

Cancer INDICATION: Cancer; breast cancer; lung cancer Mouse studies suggest the mitochondrial inhibitor ME-344 and/or the multikinase inhibitor Vargatef nintedanib could help treat kinase inhibitor-resistant cancers. In a mouse model of Stivarga regorafenib-resistant metastatic breast...
BioCentury | Jun 13, 2016
Product Development

Basket cases

Both the Genentech Inc. unit of Roche and Novartis AG are using basket trials to study targeted cancer agents more efficiently. Genentech's initial forays could yield rare subpopulation data to bring its marketed therapies into...
BioCentury | Oct 7, 2013
Finance

3Q Stock Wrap-Up: Make it a double

For the second time this year, all market cap segments closed the quarter in the black. Large caps valued at $5 billion and above gained ground for the fifth consecutive quarter. They added 12%, and...
BC Week In Review | Jul 22, 2013
Clinical News

Dovitinib lactate: Phase III data

Novartis disclosed in its 2Q13 earnings that an open-label, international Phase III trial in about 564 patients with metastatic RCC after failure of prior anti-angiogenic therapies showed that dovitinib missed the primary endpoint of improving...
BC Extra | Jul 19, 2013
Clinical News

Novartis' dovitinib misses in Phase III RCC trial

Novartis AG (NYSE:NVS; SIX:NOVN) disclosed in its 2Q13 earnings that dovitinib lactate ( TKI258 ) missed the primary endpoint of improving progression-free survival (PFS) vs. Nexavar sorafenib from Bayer AG (Xetra:BAYN) and Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) in...
BioCentury | Oct 15, 2012
Strategy

At home with Servier

Rather than follow in the footsteps of other foundation-backed mid-size European pharmas that have largely concentrated on a single therapeutic area and looked to new markets for growth, Servier has determined its path to sustainability...
BC Week In Review | Jun 13, 2011
Clinical News

Dovitinib lactate: Phase II data

Data from 59 patients in the Phase II portion of an open-label, international Phase I/II trial showed that once-daily 500 mg oral dovitinib produced 2 partial responses, 29 cases of stable disease for >=2 months...
BC Week In Review | Jun 13, 2011
Clinical News

Dovitinib lactate: Phase II data

An open-label, international Phase II trial in 20 evaluable patients with hormone receptor-positive/FGFR1+ metastatic breast cancer showed that once-daily 500 mg dovitinib produced 3 unconfirmed partial responses and 9 cases of stable disease for >=4...
BC Week In Review | Jun 1, 2009
Clinical News

Dovitinib lactate: Preliminary Phase I/II data

Preliminary data from 11 patients in a Phase I/II trial showed that oral Dovitinib lactate (TKI258) produced 1 partial response and 4 cases of stable disease. There were 2 dose-limiting toxicities of grade 4 hypertension...
Items per page:
1 - 10 of 11